ANDA 209753, held by Bionpharma. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 209753 (Methylphenidate Hydrochloride), held by Bionpharma, was first approved by FDA on Mar 2, 2018, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 2, 2018 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride5MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride20MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Feb 6, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 6, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 6, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 6, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 2, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters